Wubing Zhang
YOU?
Author Swipe
View article: Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Fig. S8 shows CD8 T cell-dependent control of tumors containing a B2m-/- population with inactivated Rnf31 and Atg5 genes.
View article: Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Fig. S7 shows effect of PD-1 inhibition on treatment of tumors containing a B2m-/- population.
View article: Table S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Table S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Table S3: ## Raw count matrix of the RNA-seq data. ## Atg5-KO vs Ctrl-KO (Veh).
View article: Supplementary Fig. S4 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S4 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Fig. S4 shows differentially expressed genes revealed by RNA-seq analysis.
View article: Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Fig. S9 shows enhanced IFNg and TNFa expression by T cells and NK cells in Rnf31/Atg5-dKO tumors.
View article: Supplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Fig. S5 shows association of Atg5-KO and Rnf31/Atg5-dKO signatures with patient survival.
View article: Supplementary Fig. S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Fig. S1 shows regulators of MHC-I independent and MHC-I dependent T cell mediated killing.
View article: Supplementary Fig. S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Fig. S3 generation of tumor cell lines with multiple gene edits.
View article: Supplementary Fig. S11 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S11 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Fig. S11 shows pharmacological sensitization of human melanoma cell line to T cell cytokines.
View article: Supplementary Fig. S2 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S2 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Fig. S2 shows efficiency of gene editing in tumor cell lines for co-dependency screen.
View article: Supplementary Fig. S6 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S6 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Fig. S6 shows functional links between autophagy and cytokine signaling pathways.
View article: Table S2 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Table S2 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Table S2: ## Raw count matrix of mini-pool CRISPR screens. ## Normalized gene scores in mini-pool screens.
View article: Supplementary Fig. S10 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S10 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Fig. S10 shows pharmacological sensitization to T cell cytokines in vitro and in vivo.
View article: Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines Open
Supplementary Table S1: # Raw count of the genome-wide CRISPR screen for identifying T cell-mediated tumor killing in B2m-deficient cells. # MAGeCK results (Gene summary) for the genome-wide CRISPR screen from the B2m-deficient cells. # Ge…
View article: Supplementary Figures from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Supplementary Figures from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity Open
Supplementary Figures S1-S8
View article: Table S4 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Table S4 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity Open
Raw count table for RNA-seq.
View article: Supplementary Data files from Hippo Signaling Pathway Regulates Cancer Cell–Intrinsic MHC-II Expression
Supplementary Data files from Hippo Signaling Pathway Regulates Cancer Cell–Intrinsic MHC-II Expression Open
Figure S1 and Figure S2
View article: Table S3 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Table S3 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity Open
Genes’ average Δβ-scores across all cancer cell lines (sheet1); Gene sets enrichment for positively (sheet2) / negatively (sheet3) selected genes in CRISPR screen. GSEA was used to perform the enrichment analysis; sgRNA sequences of AAVS1,…
View article: Improved reconstruction of single-cell developmental potential with CytoTRACE 2
Improved reconstruction of single-cell developmental potential with CytoTRACE 2 Open
While single-cell RNA sequencing has advanced our understanding of cell fate, identifying molecular hallmarks of potency—a cell’s ability to differentiate into other cell types—remains a challenge. Here we introduce CytoTRACE 2, an interpr…
View article: A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer Open
View article: Supplementary Fig. S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines
Supplementary Fig. S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines Open
Supplementary Fig. S3 generation of tumor cell lines with multiple gene edits.
View article: Supplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines
Supplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines Open
Supplementary Fig. S5 shows association of Atg5-KO and Rnf31/Atg5-dKO signatures with patient survival.
View article: Supplementary Fig. S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines
Supplementary Fig. S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines Open
Supplementary Fig. S1 shows regulators of MHC-I independent and MHC-I dependent T cell mediated killing.
View article: Supplementary Fig. S2 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines
Supplementary Fig. S2 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines Open
Supplementary Fig. S2 shows efficiency of gene editing in tumor cell lines for co-dependency screen.
View article: Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines
Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines Open
Supplementary Fig. S7 shows effect of PD-1 inhibition on treatment of tumors containing a B2m-/- population.
View article: Supplementary Fig. S6 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines
Supplementary Fig. S6 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines Open
Supplementary Fig. S6 shows functional links between autophagy and cytokine signaling pathways.
View article: Supplementary Fig. S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines
Supplementary Fig. S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines Open
Supplementary Fig. S1 shows regulators of MHC-I independent and MHC-I dependent T cell mediated killing.
View article: Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines
Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines Open
Supplementary Fig. S8 shows CD8 T cell-dependent control of tumors containing a B2m-/- population with inactivated Rnf31 and Atg5 genes.
View article: Data from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines
Data from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines Open
Tumor heterogeneity is a major barrier to cancer therapy, including immunotherapy. Activated T cells can efficiently kill tumor cells following recognition of MHC class I (MHC-I) bound peptides, but this selection pressure favors outgrowth…
View article: Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines
Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines Open
Supplementary Table S1: # Raw count of the genome-wide CRISPR screen for identifying T cell-mediated tumor killing in B2m-deficient cells. # MAGeCK results (Gene summary) for the genome-wide CRISPR screen from the B2m-deficient cells. # Ge…